Role of humoral markers in the pathogenesis of heart failure with preserved ejection fraction in patients with non-obstructive coronary artery disease

Aim. To study the role of molecular biomarkers potentially influencing the formation and progression of heart failure (HF) with preserved ejection fraction (HFpEF) in non-obstructive coronary artery disease (CAD).

Material and methods. We examined 48 patients with newly diagnosed HFpEF against the background of non-obstructive CAD. Group 1 (n=31) included patients with class I-II HF and group 2 (n=17) included patients with class III HF; the control group consisted of patients without heart failure (n=17). The content of NT-proBNP and sST2, diastolic dysfunction and coronary flow reserve parameters were assessed.

Results. The content of NT-proBNP in patients of group 1 was 45% higher than in group 2 (p<0,001). The mean levels of sST2 did not exceed the reference values and significantly exceeded the control group (p<0,001). Coronary flow reserve (CFR) decreased (p<0,001) depending on the severity of HF. Negative associations of sST2 levels with LVEF, septal e’ and CFR were revealed, as well as NT-proBNP with CFR.

Conclusion. HFpEF in non-obstructive CAD is triggered due to progressive impairment of endothelial function, which affects the decrease in coronary and myocardial flow reserves, diastolic function, hyperproduction of humoral factors that initiate perivascular fibrosis and apoptosis of cardiomyocytes.

1. Henning RJ. Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol. 2020;26;12(1):7-25. doi:10.4330/wjc.v12.i1.7.

2. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17:559-73. doi:10.1038/s41569-020-0363-2.

3. Rodríguez-Capitán J, Sánchez-Pérez A, Ballesteros-Pradas S, et al. Prognostic Implication of Non-Obstructive Coronary Lesions: A New Classification in Different Settings. J. Clin. Med. 2021;10:1863. doi:10.3390/jcm10091863.

4. Shah SJ. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. European Heart Journal. 2022:43(20):1952-4. doi:10.1093/eurheartj/ehac121.

5. Zavadovsky KV, Mochula AV, Boshchenko AA, et al. Absolute myocardial blood flows derived by dynamic CZT scan vs invasive fractional flow reserve: Correlation and accuracy. J Nucl Cardiol. 2021;28(1):249-59. doi:10.1007/s12350-019-01678-z.

6. Sušić L, Maričić L, Vincelj J, et al. Understanding the association between endothelial dysfunction and left ventricle diastolic dysfunction in development of coronary artery disease and heart failure. Acta Biomed. 2021;92(3):e2021204. doi:10.23750/abm.v92i3.11495.

7. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC: Cardiovascular Imaging. 2020;13(1, Part 2):245-57. doi:10.1016/j.jcmg.2018.12.034.

8. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(21):2625- 41. doi:10.1016/j.jacc.2018.09.042.

9. Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int J Mol Sci. 2021;22(8):3850. doi:10.3390/ijms22083850.

10. Grakova EV, Kopeva KV, Teplyakov AT, et al. Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders. Therapeutic Archive. 2019;91(1):10-37. (In Russ.) doi:10.26442/00403660.2019.01.000025.

11. Yucel O, Gul I, Zararsiz A, et al. Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz. 2018;43:455-60. doi:10.1007/s00059-017-4590-1.

12. Schill F, Persson M, Engström G, et al. Copeptin as a marker of atherosclerosis and arteriosclerosis. Atherosclerosis. 2021;338:64-8. doi:10.1016/j.atherosclerosis.2021.10.012.

13. Zalewska E, Kmieć P, Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Front. Cardiovasc. Med. 2022:9:909480. doi:10.3389/fcvm.2022.909480.

14. Zeng H, Chen J-X. Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med. 2019;6:15. doi:10.3389/fcvm.2019.00015.

15. Grakova EV, Teplyakov AT, Kopieva KV, et al. Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization. Cardiovascular Therapy and Prevention. 2018;17(5):40-6. (In Russ.) doi:10.15829/1728-8800-2018-5-40-46.